BIOMAT Database Logo BIOMAT Database Logo

[A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia]. 1998

M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov

OBJECTIVE Evaluation of effectiveness of hypolipidemic action of probucol in doses 500 and 1000 mg/day and comparison of probucol blood concentrations on the treatment month 3 and 6. METHODS Probucol (Akrikhin, Russia) was given to 41 patients with primary hypercholesterolemia in a dose 500 mg/day. 3 months later the patients were divided into two groups. Group 1 patients exhibited a > 10% decrease in cholesterol levels and continued to take probucol in the dose 500 mg/day. Group 2 patients were crossed over to higher cholesterol dose--up to 1000 mg/day. Lipids levels were measured by enzyme tests, apoproteins--by immunoturbidimetry and immunodiffusion, probucol concentrations--by high-performance liquid chromatography. RESULTS After 3 months of treatment, cholesterol lowered by 14.3 and 9.2% in groups 1 and 2, respectively. After 6 months, by 19.7 and 12.9%, respectively. Probucol concentrations in blood were higher after 6 months of treatment than after 3 months in both groups. No significant differences existed between the groups by probucol concentrations in 3 and 6 months. CONCLUSIONS Hypolipidemic effect of probucol depended on the individual features of lipoproteins metabolic disorders rather than the drug blood concentration. Larger probucol doses fail to reduce cholesterol further.

UI MeSH Term Description Entries
D006951 Hyperlipoproteinemias Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation. Hyperlipoproteinemia
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011341 Probucol A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). Biphenabid,DH-581,Lorelco,Lurselle,Panavir,Superlipid,DH 581,DH581
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia.
December 1985, Atherosclerosis,
M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
A pharmacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses.
May 1996, Biopharmaceutics & drug disposition,
M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
[Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day].
January 1986, Acta clinica Belgica. Supplementum,
M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses.
May 1998, Biopharmaceutics & drug disposition,
M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
December 2011, Therapeutic drug monitoring,
M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
[Clinical research on the hypolipidemic action of a probucol preparation].
January 1986, Vutreshni bolesti,
M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis.
February 2004, Mycoses,
M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
[Treatment of community-acquired pneumonia with levofloxacin: 500 mg once a day or 500 mg twice a day?].
January 2000, Presse medicale (Paris, France : 1983),
M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
A comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism.
October 1997, Fertility and sterility,
M G Tvorogova, and V P Lupanov, and E Iu Nuraliev, and T M Zaĭtseva, and V V Kukharchuk, and V N Titov
Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg.
April 2003, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!